RCS - Verici Dx PLC - Launch of patient-focused educational tool

Verici DxAnnouncement

31/05/2024 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe6504Qa&default-theme=true

RNS Number : 6504Q  Verici Dx PLC  31 May 2024

Non-regulatory announcement

Verici Dx plc

("Verici Dx" or the "Company")

 

Verici Dx Launches an interactive patient-focused educational tool, the
Patient Journey

Providing a detailed overview of all stages of the kidney transplant journey

 

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ
transplant, is pleased to announce the introduction of its patient-focused
education resource, for use by patients, care givers and transplant teams in
the form of a new dedicated website showing the kidney transplant patient
journey (https://patientjourney.vericidx.com
(https://patientjourney.vericidx.com) ). This online tool is designed to
illustrate a generalised pathway for patients as they consider their kidney
healthcare and offer a platform for patients to share their own experiences
digitally including video clips. It also includes video clips from transplant
team members to share their thoughts on what to expect. This enhancement is
part of Verici Dx's ongoing commitment to supporting patients with
comprehensive and accessible information.

 

At Verici Dx, we are committed to improving patient outcomes and believe that
access to reliable, detailed information is a cornerstone of effective
healthcare. This new tool provides a detailed overview of all stages of the
kidney transplant journey-from the initial diagnosis and treatment of kidney
disease, through early-stage monitoring and on to long-term care after a
kidney transplant. This resource is designed to empower patients and
caregivers with knowledge and understanding, helping them navigate the
complexities of kidney disease and transplantation with confidence.

 

The new section of the website is intended to offer a valuable tool for those
seeking guidance at each step of their journey and we look forward to
demonstrating this to patients at the Transplant Games, which will take place
in Birmingham Alabama, from 5 - 10 July 2024. We invite everyone interested
in learning more about the kidney transplant process to join us there or visit
our updated website at https://patientjourney.vericidx.com
(https://patientjourney.vericidx.com) .

 

Commenting on the update, Andrew Silverman, Director of Scientific
Communications, said:

 

"We are excited to launch this new section of the website as it directly
aligns with our mission to enhance patient care and support. It ensures that
patients and caregivers have access to the latest information and best
practices for kidney transplant care, and we are confident that it will
improve communication between all parties involved in the journey."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVFLBXZELEBBD